Novo Nordisk Gets CDSCO Panel Nod To study CDR132L
New Delhi: Novo Nordisk has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical trial of CDR132L 45.2 (45,2) mg/vial, a synthetic oligonucleotide that's being developed to treat heart failure.
This came after Novo Nordisk presented phase 2 clinical study protocol no. NN6706-8282 version 1.0 dated 21 November 2024.
CDR132L is an oligonucleotide-based inhibitor directed against miRNA132 (miR-132), designed to halt and reverse the development of detrimental cardiac remodeling. CDR132L selectively blocks aberrant miR-132 levels, leading to the reversal of cellular pathology and restoration of normal function in cardiomyocytes, contributing to improved cardiac systolic and diastolic function in patients with heart failure.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.